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Background: Predialysis hemoglobin (Hb) may overestimate the true erithropoiesis-stimulating agents (ESA)
requeriments. We tested whether predialysis Hb is a reliable predictor of the postdialysis level to better control ESA
dosage, and evaluated the relation between ESA, Hb and cardiovascular events (CVE).
Methods: Cohort study including 67 stable hemodialysis patients. Pre- and post-dialysis Hb concentrations were
measured, and ESA doses were calculated. A model to predict post-dialysis Hb is proposed. During 18 months
follow-up, CVE, hospitalizations and mortality were collected.
Results: After dialysis, Hb cocentration rise by 6.1 ± 5.6%. Using postdialysis Hb, the weight-adjusted ESA dosage
would be lower respect to the prescription using predialysis Hb: 104 ± 120 vs 128 ± 124 U/kg/week (P< 0.001).
Using predialysis Hb, 40.2% of subjects had a Hb level above 12 g/dL, whereas this percent increased to 70.1%
using postdialysis Hb. During the follow-up, 15 patients had a CVE, without differences in Hb levels respect to
subjects without CVE. However, patients with CVE had received higher ESA doses: 186 ± 180 vs 111 ± 98 U/Kg/week
(P= 0.001). The prediction model is: Postdialysis Hb (g/dL) = 1.636 + 0.871 x predialysis Hb* (g/dL) + 0.099 x UF rate**
(mL/kg/h) - 0.39 for women***. [R2 = 0.74; *P< 0,001; **P= 0.001; ***P= 0.03).
Conclusions: Postdialysis Hb can be a better reflect of the real Hb level in hemodialysis patients. Using postdialysis
Hb would avoid the use of inappropriately high ESA doses. The prediction of postdialysis Hb with an adjusted
model would help us to identify those patients at risk for ESA overdosification.Background
The introduction of erythropoiesis-stimulating agents
(ESA) has been the most important breakthrough in the
treatment of anemia associated to chronic kidney disease
(CKD). However, concomitantly with the growing know-
ledge about anemia management with ESA, new clinical
challenges have emerged, such as the definition of the op-
timal hemoglobin (Hb) target for these patients. Moreover,
this target has changed repeatedly based on security rea-
sons [1-3]. Recent randomized clinical trials have shown* Correspondence: jnavgon@gobiernodecanarias.org
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reproduction in any medium, provided the ormore frequent adverse events in patients treated to higher
Hb targets, and therefore receiving higher ESA doses [4-
7]. This opens the question about the potential harmful
effects of ESA, specially in high doses, and their potential
contribution to adverse outcomes in these patients [8]. In
addition, the potential association between ESA doses and
adverse outcomes lead to question whether ESA dosage
must be adjusted based on pre- or post-dialysis Hb values
in hemodialysis (HD) population.
Clasically, prescription of ESA in HD patients has been
based on the Hb concentration measured before the dia-
lysis session, when volume overload may underestimate
the real concentration of serum Hb. Diverse studies have
described that serum Hb concentration varies during the
HD session, and that Hb level is significantly different
when it is measured before or after dialysis, or in the
interdialysis period [9-12]. Therefore, predialysis HbLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Baseline characteristics of the patients
Age (yr) 65 ± 13 (range 31–85)
Sex (male) —no. (%) 43 (64)
Diabetes —no. (%) 29 (43.2)
Underlying disease —no. (%)
- Diabetic nephropathy 29 (43.2)
- Nephroangiosclerosis 15 (22.38)
- Glomerulonephritis 6 (8.95)
- Policystic kidney disease 8 (11.94)
- Other 9 (13.53)
Charlson Comorbidity Index 6.08 ± 2.18
Time of dialysis (minutes) 237 ± 19.58
Kt-V 1.28 ± 0.22
Ultrafiltration (ml/kg/h) 8.03 ± 2.98 (range 1.51-16.27)
EPO dose per week (U) 8,059 ± 7,712
EPO dose per Kg and week (U) 118 ± 120.24
Type of EPO—no. (%)
- darbepoetin α 11 (16.4)
- epoetin α 16 (23.8)
- epoetin β 34 (50.7)
- without EPO 6 (9)
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dosage, representing a potential risk regarding ESA-
related complications.
In the present study, we measured the Hb and
Hematocrit (Hct) levels before and after a dialysis ses-
sion in a group of stable maintenance HD patients in
order to evaluate the variation of Hb and Hct during a
dialysis session, the differences in EPO requirements and
the associated economic impact. In addition, we pro-
spectively analyzed the cardiovascular events (CVE) over
a period of 18 months, and the potential relationship
with Hb levels and EPO doses. Finally, since Hb meas-
urement after the dialysis is not an usual clinical prac-
tice, we propose an equation to predict the post-dialysis
Hb concentration based on an adjusted model.
Methods
This cohort pilot study included 67 subjects in an out-
patient hemodialysis centre at the University Hospital
Nuestra Señora de Candelaria (Santa Cruz de Tenerife,
Spain). Any research that is reported in this manuscript
has been approved by the local Ethics Committee at the
University Hospital Nuestra Señora de Candelaria, and
has been carried out in compliance with the Helsinki
Declaration. All patients gave informed consent to par-
ticipate in the study.
All patients had CKD stage 5D, under maintenance
HD for more than 6 months. There were 43 males
and 24 females, with a mean age of 65 ± 13 years
(range 31–85 years). All patients received bicarbonate
hemodialysis three times weekly with polysulfone
membranes (1.8-2 m2). The mean dialysis time was
237 ± 19 minutes (range 135–270 minutes). Regarding
the underlying renal disease, 43% of patients had dia-
betic nephropathy. Sixty-one patients (91%) were
under EPO therapy. There were no patients with
hepatitis B, hepatitis C or human immunodeficiency
virus infection. All subjects were on a stable clinical
condition with no cardiovascular events in the previ-
ous 3 months. Baseline characteristics of the patients
are shown on Table 1.
We measured the serum concentrations of Hb and
Hct before and after the midweek HD session. We col-
lected the prescribed EPO dose and calculated the dos-
age adjustment using the predialysis Hb level, as well as
the hypothetical dose adjustment using the postdialysis
Hb concentration. We calculated the difference and sav-
ings in dosage of EPO by patient and week, and the esti-
mated cost reduction. The evolution of serum Hb
concentration during an interdialysis period was ana-
lyzed in a small group of 5 patients. Serum Hb level was
measured immediately before and after the dialysis ses-
sion, and at 4, 24 and 48 hours postdialysis. In addition,
we developed an adjusted model for the estimation ofthe postdialysis Hb concentration based on gender, pre-
dialysis Hb concentration and ultrafiltration (UF) rate.
During a follow-up period of 18 months, CVE, hospi-
talizations and mortality were recorded in order to
analyze the potential relationship with Hb levels and
EPO doses. The Charlson Comorbidity Index (CCI) [13],
a score that includes age and comorbid conditions to
which a specific weight is assigned, was used for valora-
tion of comorbidity in each patient. Information was
recorded by researchers from updated medical records.
This index is used to adjust by comorbid conditions in
longitudinal studies, and it has been specifically validated
for patients with end-stage renal disease under dialysis
therapy [14].
Statistical analysis
Results for quantitative variables are expressed as mean
and standard deviation. Results for categorical variables
are expressed with frequencies and percentages. Propor-
tions were compared using the Chi-square test. Within
groups measures for continuous variables were com-
pared with Wilcoxon test and between groups compari-
son were carried out using the Mann–Whitney U
(asymptotic test) test and Wilkoxon-Mann–Whitney test
(exact test). Differences in Hb serum concentration mea-
sured at predialysis, immediately postdialysis, and 4, 24
and 48 h after the end of the dialysis session were tested
using the Wilcoxon rank test. Linear regression analysis
Table 2 Patients categorized according to pre and
postdialysis Hb
Hemoglobin (g/dL) Postdialysis
Low (<11) Normal (11-12) High (>12)
Postdialysis Low (<11) 5 6 4
7.5% 9.0% 6.0%
Normal (11-12) 1 8 16
1.5% 11.9% 23.9%
High (>12) 0 0 27
.0% .0% 40.3%
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tration using the predialysis hemoglobin level, the hourly
UF rate (mL/kg/hour) and gender as the independent
variables. Risk of CVE according to ESA dose was calcu-
lated using partial Cox regression analysis, and the
results are expressed as Hazard Ratio and its 95% confi-
dence interval. As only 15 cardiovascular events oc-
curred, the Cox models presented are not cumulative,
each used model is individual. Statistical analyses
were performed with StatXact v. 5.0.3 (Cytel Co.,
MA), STATISTICA v. 7.1 (StatSoft, OK) and SPSS v.
17.0 (Chicago, IL). P values lower than 0.05 were
considered statistically significant.
Results
The mean predialysis and postdialysis Hb concentrations
were 11.7 ± 1.1 g/dL and 12.5 ± 1.2 g/dL, respectively
(P < 0.001). The mean intradialytic percent variation
(%Δ) of Hb and Hct levels were 6.1 ± 5.6% (range: -6.5 to
17.27) and 5.8 ± 5.6% (range: -9.3 to 17.1), respectively.
The mean weight loss during dialysis was 2.19 ± 0.79 kg
(Range: 0.5 to 3.8 kg), with a mean hourly UF rate of
8.03 ± 2.98 mL/kg/h (range 1.51 to 16.27 mL/kg/h).
When comparing patients according to the UF volume,
in subjects with an UF > 2500 mL/session the mean %Δ
of Hb and Hct were 9.2 ± 4.8% and 9 ± 4.4%, respectively,
significantly higher than those observed in patients with
an UF rate < 2500 mL/session: 3.9 ± 5.2% and 3.8 ± 5.3%,
respectively (P < 0.001). Regarding the changes in serum
Hb concentration during the interdialysis period, a stat-
istical significant difference was found between the pre-
and the immediately postdialysis Hb levels (P= 0.043).
However, no differences were found between the imme-
diately postdialysis Hb concentration and those at 4 h
(P= 0.20), 24 h (P= 0.34) and 48 h (P= 0.08) after
dialysis.
According to KDOQI guidelines [1], using the predia-
lysis measurements, 37.3% of subjects had an adequate
serum Hb concentration (11–12 g/dL), whereas 15 sub-
jects (22.3%) had an inadequately low Hb level and 27
patients (40.2%) had a Hb concentration above 12 g/dL.
However, when postdialysis determinations were used,
70.1% of patients had a serum Hb concentration inad-
equately elevated (Table 2). When postdialysis measure-
ment was used, 6 out of the 15 patients (40%) with a
predialysis Hb below 11 g/dL had a Hb concentration
within the KDOQI target, whereas 16 out of the 25
patients (64%) with an adequate predialysis Hb level
showed a postdialysis Hb concentration above 12 g/dL.
Sixty-one patients (91%) were treated with EPO at the
time of the study. No baseline differences were found
between the patients with and without EPO in any vari-
able (Table 3). We analysed the hypothetical dosage ad-
justment for EPO using the postdialysis Hb concentrationas reference. If this determination was used, the weekly
prescribed EPO dose would be significantly lower than the
real EPO prescription based on predialysis Hb measure-
ment (7,03 ± 7,765 vs 8,23± 8,045 U; P< 0.001). After
adjusting for weight, the hypothetical EPO dosage using
the postdialysis Hb concentration could be reduced by
18.7% (EPO dosage using predialysis Hb, 128± 124 U/kg/
week; EPO dosage using postdialysis Hb, 104± 120 U/kg/
week).
The linear regression model to predict the postdialysis
Hb concentration is as follows: Postdialysis Hb (g/dL) =
1.636 + 0.871 x predialysis Hb* (g/dL) + 0.099 x UF
rate**(mL/kg/h) - 0.39 for women***. The adjusted coef-
ficient of determination (R2) was 0.74 (*predialysis Hb,
P < 0.001; **UFR, P= 0.001; ***gender, P= 0.031).
During the 18 months follow-up, 15 (25%) patients
had a CVE (2 stroke, 4 coronary disease, 2 cardiac
arrhythmia, 1 peripheral vascular disease, 4 arterioven-
ous fistula thrombosis and 2 mesenteric ischemia). No
differences were found between patients with and without
CVE on Hb levels (11.2± 1.43 mg/dL vs 11.9± 1.02 mg/dL,
respectively; P=0.14). However, patients who had a CVE
had received higher mean doses of EPO than those without
events: 12,133±10,562 U/week vs 7,615±6,963 U/week;
P=0.037. Adjusted by weight the differences were
186±180 vs 111±98 U/Kg/week (P=0.001). None of the 6
patients without EPO therapy presented any CVE. We
investigated whether comorbidities, expressed as Charlson
index, or adequate dialysis (as measured by Kt/V), were
confounding factors associated with CVE and EPO dose.
No association was found neither between Charlson index
and CVE (r =0.11; P=0.19), nor EPO dose (r = 0.04;
P=0.37). Regarding Kt/V, this parameter was similar in
patients with and without CVE (1.3±0.19 vs 1.3± 0.23, re-
spectively), and no association was found between Kt/V
and EPO dose (r =0.19; P=0.58). Partial Cox regression
analysis showed that controlling for ischemic heart disease
and heart failure, ESA dose is a risk factor for CVE. How-
ever, the confounding effect of age, arrthymia, diabetes, per-
ipheral vascular disease and stroke is unclear (Table 4).
Frequency of hospitalization was significantly higher in
Table 3 Baseline comorbidities categorized by ESA dose
Comorbidity - N (%) ESA dose (>18000 IU/week)
N= 7
ESA dose (≤18000 IU/week)
N= 60
P
Diabetes 3 (42.9) 26 (43.3) 0.99
Ischemic Heart Disease 1 (14.4) 20 (33.3) 0.41
Heart failure 1 (14.3) 11 (18.3) 0.99
Peripheral vascular disease 3 (42.9) 12 (20) 0.18
Stroke 0 (0) 7 (11.7) 0.99
Chronic Obstructive
Pulmonary Disease (COPD) 1 (14.3) 16 (26.7) 0.67
Arrhytmias 2 (28.6) 11 (18.3) 0.61
Tumoral History 2 (28.6) 7 (11.7) 0.24
Hepatopathy 1 (14.3) 3 (5) 0.36
Hypertension 7 (100) 58 (96.7) 0.99
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in patients with CVE (6 days [range, 3 to 12]) than in those
without CVE (0 days [range, 0 to 7]); P=0.016). A total of
13 deaths occurred during follow-up, with an increase in
the probability of death in patients with CVE (53% vs
9.63%; P <0.001).
Finally, the aplication of postdialysis Hb to calculate
the EPO dosage was associated with a reduction in cost:Table 4 Partial Cox regression models to predict CVE
controlling by age and comorbidities
HR 95% CI P
Model 1
EPO dose (IU/week) 1.015 1.010-1.020 0.032
Ischemic heart disease 2.66 0.920-7.650 0.069
Model 2
EPO dose (IU/week) 1.0015 1.001-1.002 0.049
Heart failure 2.29 0.710-7.270 0.16
Model 3
EPO dose (IU/week) 1.00 0.999-1.001 0.058
Stroke 1.72 0.380-7.750 0.47
Model 4
EPO dose (IU/week) 1.00 0.999-1.001 0.06
Age (years) 1.005 0.967-1.045 0.79
Model 5
EPO dose (IU/week) 1.000 0.999-1.001 0.065
Arrythmia 1.17 0.330-4.170 0.80
Model 6
EPO dose (IU/week) 1.000 0.999-1.001 0.094
Diabetes 0.468 0.163-1.345 0.159
Model 7
EPO dose (IU/week) 1.000 0.999-1.001 0.105
Peripheral vascular disease 1.702 0.539-5.372 0.36101 ± 111 vs 124 ± 116 euros/patient/week, respectively
(P < 0.001). In our dialysis center, for the 67 patients
included in the study, this action would have saved
83,214 euros ($ 118,858)/year.
Discussion
The main finding of our study is that the use of postdialysis
Hb concentration to monitor and adjust EPO dosage would
result in a significant reduction of EPO requeriments and
costs. Specifically, this action in the present study was asso-
ciated with a mean EPO dose decrease of 18.7% (U/Kg/
week), and a mean cost reduction of 1,242 euros/patient/
year ($ 1,774/patient/year). In addition, we present a simple
model to estimate the postdialysis Hb level based on pre-
dialysis Hb, UF rate and gender. Our suggestion about the
use of postdialysis Hb level to adjust and monitor ESA dos-
age may be a relevant issue, specially at the present mo-
ment, when the emergence of safety concerns and the
changes in clinical practice recommendations have influ-
enced physician practice in terms of reduction of target Hb,
use of ESA and dosing regimens [15].
The Food and Drug Administration has recently an-
nounced that ESA should be prescribed under a risk
management programme (the Risk Evaluation and Miti-
gation Strategy), since results from three recent rando-
mized controlled trials – the Correction of Hemoglobin
and Outcomes in Renal Insufficiency (CHOIR) [4], the
Cardiovascular Risk Reduction by Early Anemia Treat-
ment with Epoetin Beta (CREATE) [5], and the Trial to
Reduce Cardiovascular Events with Aranesp Therapy
(TREAT) [6] – showed that assigned chronic kidney dis-
ease patients (not in dialysis) to intervention with an
ESA to achieve a high versus a low Hb target was asso-
ciated with an increased risk of myocardial infarction,
stroke and death. However, almost 10 years before, the
Normal Hematocrit Trial (NHCT) [16], a study in which
more than 1200 HD patients with congestive heart
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get Hct values of 42% (normal Hct group) and 30%, had
to be stopped prematurely by the Data Safety Monitor-
ing Board because of concerns of increased cardiovascu-
lar disease risk and mortality in the normal Hct arm.
Although the majority of studies related to anemia in
HD have used predialysis Hb and Hct values, several
works have analysed the postdialysis values of Hb, show-
ing important results. Vlassopoulos et al. [9] measured
Hb and Hct in 15 stable patients before the HD sesion,
and 24, 48 and 72 hours in the interdialysis period. They
observed a significant 24 h postdialysis rise in Hb and
Hct as compared to the predialysis level, with a gradual
decrease reaching non-significant differences before the
next HD session. Similar findings were reported by
Movilli et al. [10] and Bellizzi et al. [12]. These authors
observed that Hb and Hct levels after dialysis were simi-
lar to those observed immediately at the end of the HD
session, and that these concentrations were significantly
higher than the predialysis ones. Similarly, a significant
increment in Hb and Hct levels after the HD procedure
was observed in our study. The mean percent increase
in the Hb and Hct values were 6.1% and 5.8%, respect-
ively, and rise to around 9% in patients with a body
weight loss ≥ 2.5 kg/session. Moreover, serum Hb con-
centrations measured at 4, 24 and 48 hours postdialysis
remained elevated as compared with the predialysis Hb
measurement, without significant differences respect to
the immediately postdialysis Hb level. According to
KDOQI guidelines [1], using postdialysis measurements,
70.1% of our patients had a serum Hb above 12 g/dL.
Importantly, this represents that 64% of patients with a
normal Hb target based on predialysis Hb concentration
had an inadequately high Hb level when postdialysis
determinations were used. These findings indicate that
during the first 24–48 hours after the HD session a slow
reequilibration occurs, first affecting to the extravascular
space, and then to the intravascular compartment
[10,12], suggesting that HD patients present most of the
time a Hb and Hct levels clearly higher (up to 15%) than
the predialysis values [9]. This results in the potential
exposition of these patients to excessively high Hb and
Hct concentrations for a prolonged period.
During the 18 months of follow-up in our study, 25%
of patients had a CVE. There were no differences
regarding Hb levels between patients with and without
CVE. Conversely, patients who had a CVE had received
significantly higher EPO doses than those without
events. This relationship was not affected by some base-
line comorbidities or dialysis adequacy, but probably the
small sample size makes unclear the effect of other
(i.e. diabetes, age, arrthymias, peripheral vascular disease
and stroke). In addition, no CVE were observed in the 6
patients without ESA therapy. This observation pointsto the potential adverse outcomes associated with ESA
administration, which has been suggested by other stud-
ies. Using data from the United States Renal Data Sys-
tem administrative claims, a retrospective cohort study
of more than 90,000 prevalent HD patients showed a
significant nonlinear relationship between increased
epoetin dose and mortality [17]. In another study that
comprised more than 40,000 maintenance HD patients,
an association between erythropoietin exposure and
mortality over 3 years was observed at very high doses
(> 20,000 units/week) [18]. To further analyze the rela-
tionship among patient comorbidity, ESA dosage, and
evolution with death hospitalization, myocardial infarc-
tion, stroke and heart failure as the primary compound
objective, a secondary analysis of the CHOIR study was
recently performed [8]. In the adjusted models, the risk
associated with randomization to the high-Hb group
was not significant (p = 0.49), whereas high-dose erythro-
poietin dosage was associated with a 57% higher risk of
the main variable (HR 1.57; CI: 1.04 to 2.36, p = 0.03).
Therefore, although the results of these studies did not
prove causality, they suggested that high ESA dose ra-
ther than the Hb level was associated with adverse out-
come, reinforcing the actual recommendations about the
strict adjustment of ESA dosage and the close monitori-
zation of Hb levels.
Conclusion
In conclusion, our results highlight the potential import-
ance of postdialysis Hb concentration to monitor the Hb
and Hct target levels, and to adequately adjust the ESA
dosing regimen. The use of postdialysis Hb would avoid
exposure of patients to inadequately high Hb and Hct
levels during the interdialysis period, as well as to exces-
sive ESA doses. This may be especially relevant in the
current scenario: the optimal Hb target is not yet es-
tablished, with serious safety concerns regarding ESA
therapy. Since the measurement of postdialysis Hb con-
centration might be an unfeasible practice in many HD
units, we propose an adjusted model to predict this par-
ameter. The prediction of postdialysis Hb with an
adjusted model help us to identify those patients at risk
for overdosification of ESA, and might be associated
with beneficial effects regarding cardiovascular morbid-
ity and mortality. In addition, this strategy may result in
lower ESA requeriments, or even may lead to the avoid-
ance of ESA therapy in several patients, with a beneficial
impact on the economic cost. From this economical per-
spective, the estimation of ESA dosage based on postdia-
lysis Hb concentration would represent a mean saving of
18.5%, approximately 1,242 euros ($ 1,774/patient/year).
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